A dual-sensitive nanoparticle-mediated synergistic therapy strategy involving photodynamic therapy, chemotherapy and ICD stimuli to treat breast cancer

experiments and histopathological analysis demonstrated that PPCD NPs exhibit excellent tumour targeting, high anti-tumour efficacy and low biotoxicity. These findings demonstrated the superiority of the phototherapy-chemotherapy-immunotherapy synergistic treatment strategy and indicate that PPCD NPs hold promise as a safe and effective anti-tumour nanoscale targeted drug delivery system.